| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.32 |
| 52 Week High | CN¥23.20 |
| 52 Week Low | CN¥11.32 |
| Beta | 0.67 |
| 1 Month Change | -4.79% |
| 3 Month Change | -6.95% |
| 1 Year Change | -45.85% |
| 3 Year Change | -74.49% |
| 5 Year Change | -49.30% |
| Change since IPO | -53.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2196 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 2.7% | 2.9% | 2.6% |
| 1Y | -45.8% | -15.1% | -7.4% |
Return vs Industry: 2196 underperformed the Hong Kong Pharmaceuticals industry which returned -15.1% over the past year.
Return vs Market: 2196 underperformed the Hong Kong Market which returned -7.4% over the past year.
Price Volatility
| 2196 volatility | |
|---|---|
| 2196 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2196 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2196's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 40,370 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 2196 fundamental statistics | |
|---|---|
| Market cap | HK$60.98b |
| Earnings (TTM) | HK$2.17b |
| Revenue (TTM) | HK$43.93b |
31.5x
P/E Ratio1.6x
P/S RatioIs 2196 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2196 income statement (TTM) | |
|---|---|
| Revenue | CN¥40.69b |
| Cost of Revenue | CN¥21.50b |
| Gross Profit | CN¥19.19b |
| Other Expenses | CN¥17.18b |
| Earnings | CN¥2.01b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 47.16% |
| Net Profit Margin | 4.94% |
| Debt/Equity Ratio | 57.2% |
How did 2196 perform over the long term?
See historical performance and comparison